Cyclacel Pharmaceuticals/$CYCC
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Ticker
$CYCC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Kuala Lumpur, Malaysia
Employees
12
ISIN
US23254L8761
Website
CYCC Metrics
BasicAdvanced
$5.7M
-
-$9.66
0.04
-
Price and volume
Market cap
$5.7M
Beta
0.04
Financial strength
Current ratio
5.602
Quick ratio
5.204
Long term debt to equity
0.294
Total debt to equity
0.294
Profitability
EBITDA (TTM)
-12.68
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-59,621.43%
Operating margin (TTM)
-90,607.14%
Effective tax rate (TTM)
-7.36%
Management effectiveness
Return on assets (TTM)
-160.18%
Return on equity (TTM)
-1,950.23%
Valuation
Price to revenue (TTM)
220.302
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-0.287
Free cash flow yield (TTM)
-348.70%
Free cash flow per share (TTM)
-1,244.82%
Growth
Revenue change (TTM)
-96.88%
10-year revenue growth (CAGR)
-38.64%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cyclacel Pharmaceuticals stock?
Cyclacel Pharmaceuticals (CYCC) has a market cap of $5.7M as of July 08, 2025.
What is the P/E ratio for Cyclacel Pharmaceuticals stock?
The price to earnings (P/E) ratio for Cyclacel Pharmaceuticals (CYCC) stock is 0 as of July 08, 2025.
Does Cyclacel Pharmaceuticals stock pay dividends?
No, Cyclacel Pharmaceuticals (CYCC) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Cyclacel Pharmaceuticals dividend payment date?
Cyclacel Pharmaceuticals (CYCC) stock does not pay dividends to its shareholders.
What is the beta indicator for Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals (CYCC) has a beta rating of 0.04. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.